Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 Pharmaceutical Research Report 2017

Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2017”. Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor.

Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305499

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity. 

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 12 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Musculoskeletal Disorders which include indications Dyskinesia, Anxiety Disorders, Autism, Depression, Schizophrenia, Cognitive Impairment Associated With Schizophrenia (CIAS), Major Depressive Disorder, Alcohol Addiction, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Chronic Pain, Cognitive Disorders, Cognitive Impairment, DiGeorge Syndrome, Fragile X Syndrome, Generalized Anxiety Disorder (GAD), Mania, Neurology, Opium (Opioid) Addiction, Pain, Parkinson's Disease, Spasmodic Torticollis and Substance (Drug) Abuse. 

The latest report Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Full Report With TOC: http://www.marketresearchhub.com/report/metabotropic-glutamate-receptor-5-gprc1e-or-mglur5-or-grm5-pipeline-review-h2-2017-report.html

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview 8
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment 19
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development 23
Addex Therapeutics Ltd 23
Aevi Genomic Medicine Inc 23
Bristol-Myers Squibb Company 24
Eisai Co Ltd 24
Eli Lilly and Company 25
Heptares Therapeutics Ltd 25
Johnson & Johnson 26
Merz Pharma GmbH & Co KgaA 26
Novartis AG 27
Richter Gedeon Nyrt 27
Sumitomo Dainippon Pharma Co Ltd 28
Toray Industries Inc 28
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles 29
alloswitch-1 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BMS-952048 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
BMS-955829 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
dipraglurant ER - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
dipraglurant IR - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1305499

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 800-998-4852 (US-Canada)
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.